May 28, 2020
The U.S. Food and Drug Administration has approved Imoxi Topical Solution for Cats, the first generic version of a topical imidacloprid and moxidectin product for the following indications: the prevention of heartworm disease; the killing of adult fleas and treatment of flea infestations; the treatment and control of ear mite infestations; and for certain life cycle phases of hookworm and roundworm intestinal parasites. Imoxi Topical Solution for Cats is available by prescription only because a veterinarian’s expertise is needed to diagnose parasitic disease and determine the appropriate treatment.
Imoxi Topical Solution for Cats contains the same active ingredients (imidacloprid and moxidectin) in the same concentrations and dosage form as the approved brand name drug product, Advantage Multi for Cats, which was first approved in 2007. In addition, the FDA determined that Imoxi Topical Solution for Cats contains no inactive ingredients that may significantly affect the bioavailability of the active ingredients.
Vetoquinol USA, Inc. is the sponsor of Imoxi Topical Solution for Cats. Vetoquinol USA, Inc. is also the sponsor of Imoxi Topical Solution for Dogs, which earned FDA approval in December 2019.
For more information:
Issued by FDA Center for Veterinary Medicine.
For questions, Contact CVM.